Reduction of exposure to tacrolimus trough level variability is associated with better graft survival after kidney transplantation
High tacrolimus trough drug level variability was found to be associated with reduced graft survival. The primary goal of this study was to find whether reduction of exposure to high tacrolimus trough level variability in patients in which previously had high variability was associated with better graft survival.
All tacrolimus drug level values in patients that underwent kidney transplantation at our center between 2006 and 2015 were collected. Exposure to variability was calculated using a time-weighted coefficient of variability (TWCV). Time-dependent univariate and multivariate Cox proportional hazard models were used to analyze the primary outcome of graft survival and to determine a cutoff value for TWCV as a predictor of this outcome.
A total of 878 patients were included in the study with a median follow-up of 1263 days. TWCV above 25% was significantly associated with reduced graft survival (HR3.66, 95% CI 2.3–5.8, p < 0.001). Of the 480 patients (54.7%) who had a cumulative TWCV of > 25% at a certain time during the follow-up, 110 (22.9%) later returned to a cumulative TWCV of less than 25%. Reduction of TWCV to values below 25% was associated with a hazard of graft loss that was not different from patients who had cumulative TWCV of less than 25% during the entire follow-up period (HR 1.81, 95% CI 0.71–4.62, p = 0.218 and HR 1.08, 95% CI 0.39–2.99, p = 0.780) in univariate and multivariate analyses, respectively.
Monitoring TWCV can help detect the high-risk patients. Interventions intended to reduce variability on long-term graft survival may have a positive effect on graft survival.
KeywordsKidney transplantation Tacrolimus Trough levels Variability Graft survival
Rahamimov Ruth: conceived the study, drafted the manuscript, provided intellectual content of critical importance to the work and approved the version to be published.
Tifti-Orbach Hagit: collected the data, provided intellectual content of critical importance to the work, and approved the version to be published.
Zingerman Boris: provided intellectual content of critical importance to the work and approved the version to be published.
Green Hefziba: provided intellectual content of critical importance to the work and approved the version to be published.
Schneider Shira: provided intellectual content of critical importance to the work and approved the version to be published.
Chagnac Avry: provided intellectual content of critical importance to the work, revised and approved the version to be published.
Mor Eytan: provided intellectual content of critical importance to the work, revised the manuscript, and approved the version to be published.
Fox Benjamin D: designed the study, provided intellectual content of critical importance to the work, revised the manuscript, and approved the version to be published.
Rozen-Zvi Benaya: designed the study, analyzed the data, revised the manuscript, provided intellectual content of critical importance to the work, and approved the version to be published.
Compliance with ethical standards
The study was approved by the RMC Institutional Review Board and was conducted according to the declaration of Helsinki and the declaration of Istanbul.
Conflict of interest
Ruth Rahamimov received a fee for participation in advisory boards from Novartis and Teva.
Benaya Rozen-Zvi received a consultation fee from Fresenius Medical and a Lecture fee from Novartis
- 3.Borra LC, Roodnat JI, Kal JA, Mathot RA, Weimar W, van Gelder T (2010) High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant 25(8):2757–2763. https://doi.org/10.1093/ndt/gfq096 CrossRefGoogle Scholar
- 5.Rozen-Zvi B, Schneider S, Lichtenberg S, Green H, Cohen O, Gafter U, Chagnac A, Mor E, Rahamimov R (2017) Association of the combination of time-weighted variability of tacrolimus blood level and exposure to low drug levels with graft survival after kidney transplantation. Nephrol Dial Transplant 32(2):393–399. https://doi.org/10.1093/ndt/gfw394 Google Scholar
- 6.O'Regan JA, Canney M, Connaughton DM, O'Kelly P, Williams Y, Collier G, deFreitas DG, O'Seaghdha CM, Conlon PJ (2016) Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation. J Nephrol 29(2):269–276. https://doi.org/10.1007/s40620-015-0230-0 CrossRefGoogle Scholar
- 7.Shuker N, Shuker L, van Rosmalen J, Roodnat JI, Borra LC, Weimar W, Hesselink DA, van Gelder T (2016) A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation. Transpl Int 29(11):1158–1167. https://doi.org/10.1111/tri.12798 CrossRefGoogle Scholar
- 8.Rodrigo E, Segundo DS, Fernandez-Fresnedo G, Lopez-Hoyos M, Benito A, Ruiz JC, de Cos MA, Arias M (2016) Within-patient variability in tacrolimus blood levels predicts kidney graft loss and donor-specific antibody development. Transplantation 100(11):2479–2485. https://doi.org/10.1097/TP.0000000000001040 CrossRefGoogle Scholar
- 11.Kidney Disease: Improving Global Outcomes Transplant Work G (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9 Suppl 3:S1–155. doi: https://doi.org/10.1111/j.1600-6143.2009.02834.x
- 12.De Pasquale C, Veroux M, Fornaro M, Sinagra N, Basile G, Gozzo C, Santini R, Costa A, Pistorio ML (2016) Psychological perspective of medication adherence in transplantation. World J Transplant 6 (4):736–742. doi: https://doi.org/10.5500/wjt.v6.i4.736
- 13.Christina S, Annunziato RA, Schiano TD, Anand R, Vaidya S, Chuang K, Zack Y, Florman S, Shneider BL, Shemesh E (2014) Medication level variability index predicts rejection, possibly due to nonadherence, in adult liver transplant recipients. Liver Transpl 20(10):1168–1177. https://doi.org/10.1002/lt.23930 CrossRefGoogle Scholar
- 14.Huang CT, Shu KH, Ho HC, Wu MJ (2016) Higher variability of tacrolimus trough level increases risk of acute rejection in kidney transplant recipients. Transplant Proc 48(6):1978–1980. https://doi.org/10.1016/j.transproceed.2016.02.081 CrossRefGoogle Scholar
- 22.Lemahieu W, Maes B, Verbeke K, Rutgeerts P, Geboes K, Vanrenterghem Y (2005) Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am J Transplant 5(6):1383–1391. https://doi.org/10.1111/j.1600-6143.2005.00844.x CrossRefGoogle Scholar
- 23.Wu MJ, Cheng CY, Chen CH, Wu WP, Cheng CH, Yu DM, Chuang YW, Shu KH (2011) Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients. Transplantation 92(6):648–652. https://doi.org/10.1097/TP.0b013e3182292426 CrossRefGoogle Scholar
- 24.Kuypers DR, Peeters PC, Sennesael JJ, Kianda MN, Vrijens B, Kristanto P, Dobbels F, Vanrenterghem Y, Kanaan N, Team AS (2013) Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation 95(2):333–340. https://doi.org/10.1097/TP.0b013e3182725532 CrossRefGoogle Scholar